Borosil Scientific Limited has informed the Exchange about Investor Presentation
BOROSCI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Borosil Scientific filed its investor presentation for Q3FY26 and 9MFY26 standalone and consolidated results. The company highlighted that standalone EBITDA grew in 9MFY26 despite one-time expenses from discontinuing operations at its Ambad plant, while consolidated EBITDA declined due to weaker sales at Goel Scientific Glass Works. The Process Systems segment saw a Rs 3.75 crore revenue reversal in Q3FY26, with some high-value orders deferred to later quarters. The company set medium-term goals of achieving 12-14% revenue CAGR and improving EBITDA margins, with a focus on higher-margin Process Sciences and Lab Equipment segments, annual pricing actions, and tighter expense control.
Mixed signals for shareholders — near-term headwinds from one-time charges and Process Systems weakness, but medium-term margin expansion guidance and a clear growth roadmap (Make in India, exports, new products) could support the stock if execution holds.